Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
View Top Employees from Sunesis Pharmaceuticals, Inc.Website | http://www.sunesis.com |
Ticker | SNSS |
Revenue | $2 million |
Funding | $57 million |
Employees | 43 (34 on RocketReach) |
Founded | 1987 |
Address | 395 Oyster Point Blvd. Ste. 400, South San Francisco, California 94080, US |
Phone | (650) 266-3500 |
Fax | (650) 266-3505 |
Technologies |
JavaScript,
HTML,
PHP
+25 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Pharmaceutical |
Web Rank | 3 Million |
Keywords | Sunesis, Snss Sunesis Pharmaceuticals Inc., Sunesis Pharmaceuticals Offering, Acalabrutinib C481s Ic50, Study 062-Hsp-101 Sunesis |
Competitors | Calithera Biosciences, Diffusion Pharmaceuticals, G1 Therapeutics, Inc., Proteostasis Therapeutics, Inc. (PTI), Sequella, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies |
Looking for a particular Sunesis Pharmaceuticals, Inc. employee's phone or email?
The Sunesis Pharmaceuticals, Inc. annual revenue was $2 million in 2024.
Mary Bolton is the Vice President of Clinical Development of Sunesis Pharmaceuticals, Inc..
34 people are employed at Sunesis Pharmaceuticals, Inc..
Sunesis Pharmaceuticals, Inc. is based in South San Francisco, California.
The NAICS codes for Sunesis Pharmaceuticals, Inc. are [3254, 32541, 325, 5417, 541, 54, 32].
The SIC codes for Sunesis Pharmaceuticals, Inc. are [28, 283].